Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Medtech
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds and APIs
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
Multimedia
Blog
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Breadcrumb
Home
Vantage
Pharmaceutical Companies
Serono
October 20, 2015
Interview – Karolinska focuses, but not on early-stage medtech
July 09, 2014
Huge second quarter for M&A sets 2014 on track for record year
June 19, 2014
For oncology deals, don’t forget the other Merck
April 10, 2014
Myriad moves to turn homebrew into companion diagnostic, but path is risky
July 15, 2013
EP Vantage interview – Auxogyn’s viability boosted by embryo selection tool
November 22, 2012
EP Vantage Interview – Poxel treading novel path to diabetes success
September 19, 2012
Pharma’s hatchet men ask, are you local?
September 06, 2012
Symphogen reaps second Sym004 harvest with Merck Serono deal
May 14, 2012
EP Vantage Interview - F-Star to push forward with bispecific antibody pipeline
November 04, 2011
Ablynx and ImmuPharma dealing with big pharma rejection
April 20, 2011
Vantage Point - Corporate VCs put into perspective
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
September 22, 2022
ESMO 2022 eBook
September 01, 2022
PD(L)anner – September 2022
Editor's Picks
July 27, 2022
Aids 2022 preview – Gilead shoots for an HIV cure
July 21, 2022
Private equity gets serious about drug development
July 18, 2022
Unpacking Royalty Pharma
July 19, 2022
No plain sailing for Novartis’s PD-1 plan
July 26, 2022
Move over Aduhelm, it’s tofersen’s turn
